Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HBB | P68871 | 1/20 | 0.31 |
| ▸ | KDM5A | P29375 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23468935 | 0.98 | CA12 (0.32) | MAPTKDM5AKDM4C | |
| SCHEMBL20445471 | 0.90 | MAPT (0.38) | MAPTLMNATP53TSHRHTT | |
| SCHEMBL24597026 | 0.85 | CYP2C9 (0.31) | — | |
| SCHEMBL25828466 | 0.85 | KDM4C (0.39) | KDM5AKDM4C | |
| SCHEMBL26142260 | 0.84 | CA12 (0.32) | MAPT | |
| SCHEMBL13919919 | 0.83 | — | — | |
| SCHEMBL23945777 | 0.83 | SIGMAR1 (0.41) | KDM5AKDM4C | |
| SCHEMBL22305826 | 0.82 | CYP2C19 (0.33) | TSHR | |
| SCHEMBL25566663 | 0.81 | PRMT1 (0.46) | MAPTLMNATP53TSHRHTT | |
| SCHEMBL25566781 | 0.81 | CHRM2 (0.32) | MAPTLMNATP53TSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159532-A1 | PARATHYROID HORMONE (PTH) RECEPTOR ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2023-05-25 | — | — | US | disclosed |
| EP-4019521-A1 | AZAHETEROARYL COMPOUND AND APPLICATION THEREOF | Blueray Therapeutics (Shanghai) Co., Ltd (CN) | 2022-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159532-A1 | PARATHYROID HORMONE (PTH) RECEPTOR ANTAGONISTS AND USES THEREOF | PTH1R, CALCR, VDR | MAPT 3301/4885LMNA 1955/4885TP53 1208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.